Literature DB >> 11516777

Nasal vaccines.

S S Davis1.   

Abstract

The nasal route for vaccination offers some important opportunities, especially for the prophylaxis of respiratory diseases. Vaccination via the respiratory tract is reviewed and the deposition and clearance of antigens in the deep lung and nose are described and contrasted. Lymphoid structures in the respiratory tract differ according to species; the rat and mouse have a well developed nose-associated lymphoid tissue, while in man, the structure known as Waldeyer's ring (that includes the tonsils), is important as an induction site. The immune response following intranasal administration can provide protection at the administration site and at various effector sites as part of the common mucosal immune system. A number of formulation considerations are important when designing novel systems for nasal administration as are physiological factors such as mucociliary clearance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11516777     DOI: 10.1016/s0169-409x(01)00162-4

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  73 in total

1.  Evaluation of a temperature-restricted, mucosal tuberculosis vaccine in guinea pigs.

Authors:  Tuhina Gupta; Monica LaGatta; Shelly Helms; Rebecca L Pavlicek; Simon O Owino; Kaori Sakamoto; Tamas Nagy; Stephen B Harvey; Mark Papania; Stephanie Ledden; Kevin T Schultz; Candace McCombs; Frederick D Quinn; Russell K Karls
Journal:  Tuberculosis (Edinb)       Date:  2018-10-19       Impact factor: 3.131

Review 2.  Absorption enhancers for nasal drug delivery.

Authors:  Stanley S Davis; Lisbeth Illum
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Mucosal adjuvant properties of the Shigella invasin complex.

Authors:  Robert W Kaminski; K Ross Turbyfill; Edwin V Oaks
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Correlation of SEC/MALLS with ultracentrifuge and viscometric data for chitosans.

Authors:  Monica Fee; Neil Errington; Kornelia Jumel; Lisbeth Illum; Alan Smith; Stephen E Harding
Journal:  Eur Biophys J       Date:  2003-06-14       Impact factor: 1.733

Review 5.  Mucosal vaccines: recent progress in understanding the natural barriers.

Authors:  Olga Borges; Filipa Lebre; Dulce Bento; Gerrit Borchard; Hans E Junginger
Journal:  Pharm Res       Date:  2009-12-01       Impact factor: 4.200

6.  Non-random lymphocyte distribution among virus-infected cells of the respiratory tract.

Authors:  Rajeev Rudraraju; Robert E Sealy; Sherri L Surman; Paul G Thomas; Barry H Dayton; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2013-12       Impact factor: 2.257

7.  Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity.

Authors:  Pamela T Wong; Su He Wang; Susan Ciotti; Paul E Makidon; Douglas M Smith; Yongyi Fan; Charles F Schuler; James R Baker
Journal:  Mol Pharm       Date:  2013-12-13       Impact factor: 4.939

8.  Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis.

Authors:  Lihao Chen; Jun Wang; Anna Zganiacz; Zhou Xing
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin.

Authors:  Daniel Carapau; Robert Mitchell; Adéla Nacer; Alan Shaw; Caroline Othoro; Ute Frevert; Elizabeth Nardin
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

10.  Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.